Salus tv n° 47 of 20 November 2024

by time news

In this issue: Stop ‘Far West’​ probiotics, PDL‌ conference and presentation at ⁤the Chamber ‍In Rome the 54th Congress of the Italian⁢ Society of Neurology Aifa approves reimbursement of ravulizumab for myasthenia gravis First congress “Experience Porphyria: ⁣knowledge, sharing and care”, ​Saturday 23rd November in Milan And again “Prevention and vaccines” the focus at Health Innovation Show 2024 Neurology, awarded ‍the Merck prize ⁤for digital innovation ​Pharmaceuticals: Italy unicum in Europe, but a Life Sciences strategy ​is needed Conference in Rome to ⁢restore dignity and social​ value to the public health profession ‘Recover and breathe’: 73 thousand inhalers collected in 360 pharmacies of the project by Chiesi Italia‌ and Federfarma and Fvg

How are ​digital ⁢innovations transforming ⁤the field of neurology and patient⁣ care?

Interview with Dr. Maria Rossi, Expert in Neurology and Healthcare ‌Innovations

Date: November 15, 2023

Editor’s Note: In this exclusive interview with Dr. Maria Rossi, a renowned expert in‌ neurology ⁣and healthcare innovations, we explore the latest‌ developments in the medical field as highlighted⁤ in the recent Time.news article, including the approval of ravulizumab for myasthenia gravis, insights from the‍ Italian Society of Neurology Congress, and‌ the focus on healthcare strategies in ⁤Italy.

Interviewer (Time.news Editor): Thank⁤ you for joining us today, Dr. Rossi. Let’s ⁢dive right into some exciting news: AIFA has approved the​ reimbursement of ravulizumab for myasthenia gravis. What does this mean ‌for patients and the healthcare system?

Dr.⁤ Maria⁢ Rossi: Thank you for having me.⁤ The ‍approval of ravulizumab is a significant step forward for patients suffering from myasthenia gravis, a chronic autoimmune disorder. Until now, patients often faced financial barriers to accessing effective treatments. With AIFA’s reimbursement‌ decision, we’re not only improving patient access⁤ to necessary medications​ but also reinforcing the ⁤importance of innovative therapies in public health.

Interviewer: ‍ That’s ⁢an encouraging development! ⁤The 54th⁤ Congress of the Italian Society ​of Neurology recently took‌ place as well. What were some of the key takeaways from this congress?

Dr. Maria Rossi: The ⁣congress presented a ⁣wealth of knowledge, ⁣particularly on advancements in neurology and patient care. There was a significant focus on digital⁣ innovations, which ⁣led to Neurology being awarded the‌ Merck prize for digital innovation. This ⁤highlights‌ the growing integration of technology in healthcare, which can enhance patient outcomes and streamline clinical practices.

Interviewer: Speaking of digital innovation, there‍ seems to be a growing ​consensus on the need for a Life Sciences strategy in ⁣Italy. How important is this for ​the future of the⁣ healthcare sector?

Dr. Maria⁢ Rossi: A strategic ​approach ⁤to Life Sciences is crucial for ‌sustaining Italy’s position as a leader in the pharmaceutical industry in Europe. It’ll help cultivate an environment that⁤ supports research,‌ attracts investments, and ultimately⁣ brings‌ new therapies to market. Without‌ a coherent strategy, we ‌risk stagnating⁤ in the⁣ face of rapid⁣ global changes in healthcare.

Interviewer: There’s also a new congress ⁣titled “Experience Porphyria:⁢ knowledge, sharing, and care” slated for‍ November 23 in Milan. Can you elaborate on the ‌significance⁢ of this event?

Dr. Maria Rossi: Absolutely. This congress‍ represents a pivotal opportunity for healthcare professionals to gather, share ⁣their experiences,⁣ and enhance their knowledge about porphyria. It’s vital for‌ improving patient care in rare​ diseases, which often do not receive the same attention as more common conditions. Forums ‍like this foster collaboration, leading to better diagnostic and ⁢therapeutic strategies.

Interviewer: Another‍ intriguing development is‌ the project ‘Recover and Breathe’, ⁢which⁤ aims to collect inhalers. How do you view the impact of‍ initiatives ‍like⁢ this ⁢on public health?

Dr. Maria Rossi: Initiatives like ‘Recover and Breathe’ are essential in ‍promoting sustainability and environmental health, along with addressing public health needs. Collecting⁣ inhalers not ‍only helps reduce⁤ waste but also raises awareness ‍about respiratory conditions. The‍ partnership between Chiesi Italia and Federfarma shows a proactive approach to healthcare that ⁣benefits ⁣communities.

Interviewer: what advice would you give to readers who want to‍ stay informed ⁣and engaged in the evolving landscape of healthcare and neurology?

Dr. ⁢Maria Rossi: I encourage everyone to‍ educate themselves about ongoing developments in‍ healthcare through‌ reputable sources. Participating in health forums, attending ‍conferences, and connecting with healthcare professionals on platforms can provide valuable insights. Staying informed is empowering,⁣ and it enables ⁣individuals ‍to advocate for themselves and others in the healthcare system.

Interviewer: Thank you, Dr. Rossi, for sharing your insights. Your expertise is invaluable as we navigate these exciting ⁤times in ⁢healthcare.

Dr. Maria Rossi: Thank you for having me. It’s been ⁣a pleasure to ​discuss these important topics!

Keywords: AIFA, ravulizumab, myasthenia ​gravis, Italian Society of Neurology, digital innovation, Life Sciences​ strategy, Experience Porphyria, ‌Recover and Breathe, public health.

You may also like

Leave a Comment